{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:44:58Z","timestamp":1787031898942,"version":"build-2736575974"},"reference-count":70,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2020]]},"DOI":"10.5387\/fms.2020-02","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T18:07:08Z","timestamp":1584036428000},"page":"1-9","source":"Crossref","is-referenced-by-count":31,"title":["Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers"],"prefix":"10.5387","volume":"66","author":[{"given":"Shuzo","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yashiro-Furuya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.  Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus:pathogenesis and biomarkers. Nat Rev Neurol, <b>10<\/b>:579-596, 2014. doi:10.1038\/nrneurol.2014.148.","DOI":"10.1038\/nrneurol.2014.148"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2.  Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus:Current Approaches and Future Perspectives. Drugs, <b>76<\/b>:459-483, 2016. doi:10.1007\/s40265-015-0534-3.","DOI":"10.1007\/s40265-015-0534-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3.  [No authors listed]. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum, <b>42<\/b>:599-608, 1999.","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"4","unstructured":"4.  Hanly JG, Urowitz MB, Sanchez-Guerrero J, <i>et al.<\/i> Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus:an international inception cohort study. Arthritis Rheum, <b>56<\/b>:265-273, 2007."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.  Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol, <b>6<\/b>:358-367, 2010. doi:10.1038\/nrrheum.2010.62.","DOI":"10.1038\/nrrheum.2010.62"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.  Govoni M, Bortoluzzi A, Padovan M, <i>et al.<\/i> The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun, <b>74<\/b>:41-72, 2016. doi:10.1016\/j.jaut.2016.06.013.","DOI":"10.1016\/j.jaut.2016.06.013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.  Kampylafka EI, Alexopoulos H, Kosmidis ML, <i>et al.<\/i> Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus:a 3-year prospective study of 370 patients. PLoS One, <b>8<\/b>:e55843, 2013. doi:10.1371\/journal.pone.0055843.","DOI":"10.1371\/journal.pone.0055843"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.  Sato S, Yashiro M, Asano T, Kobayashi H, Watanabe H, Migita K. Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol,<b> 36<\/b>:1655-1659, 2017. doi:10.1007\/s10067-017-3653-2.","DOI":"10.1007\/s10067-017-3653-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.  McGlasson S, Wiseman S, Wardlaw J, Dhaun N, Hunt DPJ. Neurological Disease in Lupus: Toward a Personalized Medicine Approach. Front Immunol, <b>9<\/b>:1146, 2018. doi:10.3389\/fimmu.2018.01146. eCollection 2018.","DOI":"10.3389\/fimmu.2018.01146"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.  Namjou B, Kothari PH, Kelly JA, <i>et al.<\/i> Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun, <b>12<\/b>:270-279, 2011. doi:10.1038\/gene.2010.73.","DOI":"10.1038\/gene.2010.73"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.  Ellyard JI, Jerjen R, Martin JL, <i>et al.<\/i> Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing. Arthritis Rheumatol, <b>66<\/b>: 3382-3386, 2014.","DOI":"10.1002\/art.38824"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.  Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell, <b>134<\/b>:587-598, 2008. doi:10.1016\/j.cell.2008.06.032.","DOI":"10.1016\/j.cell.2008.06.032"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.  Lundstr\u00f6m E, Gustafsson JT, J\u00f6nsen A, <i>et al.<\/i> HLA-DRB1*04\/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis, <b>72<\/b>:1018-1025, 2013. doi:10.1136\/annrheumdis-2012-201760.","DOI":"10.1136\/annrheumdis-2012-201760"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.  Svenungsson E, Gustafsson J, Leonard D, <i>et al.<\/i> A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis, <b>69<\/b>:834-840, 2010. doi:10.1136\/ard.2009.115535.","DOI":"10.1136\/ard.2009.115535"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15.  Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis, <b>72<\/b> Suppl 2:ii56-61, 2013. doi:10.1136\/annrheumdis-2012-202351.","DOI":"10.1136\/annrheumdis-2012-202351"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16.  Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol, <b>28<\/b>:497-505, 2016. doi:10.1097\/BOR.0000000000000318.","DOI":"10.1097\/BOR.0000000000000318"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.  Rhiannon JJ. Systemic lupus erythematosus involving the nervous system:presentation, pathogenesis, and management. Clin Rev Allergy Immunol, <b>34<\/b>:356-360, 2008. doi:10.1007\/s12016-007-8052-z.","DOI":"10.1007\/s12016-007-8052-z"},{"key":"18","unstructured":"18.  Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol, <b>19<\/b>:732-741, 1992."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19.  Mehta N, Uchino K, Fakhran S, <i>et al.<\/i> Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke, <b>39<\/b>:3236-3241, 2008.    doi:10.1161\/STROKEAHA.108.514687.","DOI":"10.1161\/STROKEAHA.108.514687"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.  Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol, <b>10<\/b>:338-347, 2014. doi:10.1038\/nrrheum.2014.15.","DOI":"10.1038\/nrrheum.2014.15"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21.  Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus, <b>25<\/b>:997-1003, 2016. doi:10.1177\/0961203316629556.","DOI":"10.1177\/0961203316629556"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22.  Ainiala H, Hietaharju A, Dastidar P, <i>et al.<\/i> Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum, <b>50<\/b>:858-865, 2004.","DOI":"10.1002\/art.20045"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24.  Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis, <b>37<\/b>:13-25, 2010. doi:10.1016\/j.nbd.2009.07.030.","DOI":"10.1016\/j.nbd.2009.07.030"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25.  Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A. Mechanisms of neuropsychiatric lupus:The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun, <b>91<\/b>:34-44, 2018. doi:10.1016\/j.jaut.2018.03.001.","DOI":"10.1016\/j.jaut.2018.03.001"},{"key":"25","unstructured":"26.  Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus:more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum, <b>34<\/b>:501-537, 2004."},{"key":"26","doi-asserted-by":"crossref","unstructured":"27.  Harris EN, Pierangeli S. Antiphospholipid antibodies and cerebral lupus. Ann N Y Acad Sci, <b>823<\/b>:270-278, 1997.","DOI":"10.1111\/j.1749-6632.1997.tb48400.x"},{"key":"27","unstructured":"28.  Sanna G, Bertolaccini ML, Cuadrado MJ. Neuropsychiatric manifestations in systemic lupus erythematosus:prevalence and association with antiphospholipid antibodies. J Rheumatol, <b>30<\/b>:985-992, 2003."},{"key":"28","doi-asserted-by":"crossref","unstructured":"29.  Hanly JG. Attribution in the assessment of nervous system disease in SLE. Rheumatology (Oxford), <b>54<\/b>:755-756, 2015. doi:10.1093\/rheumatology\/keu458.","DOI":"10.1093\/rheumatology\/keu458"},{"key":"29","unstructured":"30.  Andrade RM, Alarc\u00f3n GS, Gonz\u00e1lez LA, <i>et al.<\/i> Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis, <b>67<\/b>:829-834, 2008."},{"key":"30","unstructured":"31.  Mok MY, Chan EY, Fong DY, Leung KF, Wong WS, Lau CS. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol, <b>32<\/b>:622-628, 2005."},{"key":"31","doi-asserted-by":"crossref","unstructured":"32.  McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology, <b>64<\/b>:297-303, 2005.","DOI":"10.1212\/01.WNL.0000149640.78684.EA"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33.  Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, Chapman J. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol, <b>272<\/b>:10-15, 2014. doi:10.1016\/j.jneuroim.2014.04.003.","DOI":"10.1016\/j.jneuroim.2014.04.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34.  Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, Bl\u00fcthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med (Berl), <b>81<\/b>:194-204, 2003.","DOI":"10.1007\/s00109-003-0423-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35.  Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis, <b>51<\/b>:1053-1055, 1992.","DOI":"10.1136\/ard.51.9.1053"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36.  Haddouk S, Marzouk S, Jallouli M, <i>et al.<\/i> Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford), <b>48<\/b>:953-957, 2009. doi:10.1093\/rheumatology\/kep142.","DOI":"10.1093\/rheumatology\/kep142"},{"key":"36","unstructured":"37.  Karassa FB, Afeltra A, Ambrozic A, <i>et al.<\/i> Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus:an international meta-analysis. Arthritis Rheum, <b>54<\/b>:312-324, 2006."},{"key":"37","doi-asserted-by":"crossref","unstructured":"38.  Bonfa E, Golombek SJ, Kaufman LD, <i>et al.<\/i> Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med, <b>317<\/b>:265-271, 1987.","DOI":"10.1056\/NEJM198707303170503"},{"key":"38","unstructured":"39.  West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus:a 10-year prospective study on the value of diagnostic tests. Am J Med, <b>99<\/b>:153-163, 1995."},{"key":"39","unstructured":"40.  Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus:diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus, <b>5<\/b>:178-183, 1996."},{"key":"40","doi-asserted-by":"crossref","unstructured":"41.  Briani C, Lucchetta M, Ghirardello A, <i>et al.<\/i> Neurolupus is associated with anti-ribosomal P protein antibodies:an inception cohort study. J Autoimmun, <b>32<\/b>:79-84, 2009. doi:10.1016\/j.jaut.2008.12.002.","DOI":"10.1016\/j.jaut.2008.12.002"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42.  Hanly JG, Urowitz MB, Siannis F, <i>et al.<\/i> Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis:results from an international inception cohort study. Arthritis Rheum, <b>58<\/b>:843-853, 2008.   doi:10.1002\/art.23218.","DOI":"10.1002\/art.23218"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43.  Katzav A, Solodeev I, Brodsky O, <i>et al.<\/i> Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum, <b>56<\/b>:938-948, 2007.","DOI":"10.1002\/art.22419"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44.  Matus S, Burgos PV, Bravo-Zehnder M, <i>et al.<\/i> Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med,<b> 204<\/b>: 3221-3234, 2007.","DOI":"10.1084\/jem.20071285"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45.  Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol, <b>259<\/b>:622-629, 2012. doi:10.1007\/s00415-011-6232-5.","DOI":"10.1007\/s00415-011-6232-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46.  Kowal C, DeGiorgio LA, Nakaoka T, <i>et al.<\/i> Cognition and immunity;antibody impairs memory. Immunity, <b>21<\/b>:179-188, 2004.","DOI":"10.1016\/j.immuni.2004.07.011"},{"key":"46","unstructured":"47.  Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior:antibodies alter emotion. Proc Natl Acad Sci U S A, <b>103<\/b>: 678-683, 2006."},{"key":"47","doi-asserted-by":"crossref","unstructured":"48.  DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med, <b>7<\/b>:1189-1193, 2001.","DOI":"10.1038\/nm1101-1189"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49.  Husebye ES, Sthoeger ZM, Dayan M, <i>et al.<\/i> Autoantibodies to a NR2A peptide of the glutamate\/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis, <b>64<\/b>: 1210-1213, 2005.","DOI":"10.1136\/ard.2004.029280"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50.  Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum, <b>58<\/b>: 1130-1115, 2008. doi:10.1002\/art.23399.","DOI":"10.1002\/art.23399"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51.  Fragoso-Loyo H, Cabiedes J, Orozco-Narv\u00e1ez A, <i>et al.<\/i> Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One, <b>3<\/b>:e3347, 2008. doi:10.1371\/journal.pone.0003347.","DOI":"10.1371\/journal.pone.0003347"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52.  Yoshio T, Okamoto H, Hirohata S, Minota S. IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum, <b>65<\/b>: 457-463, 2013. doi:10.1002\/art.37745.","DOI":"10.1002\/art.37745"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53.  Hirohata S, Arinuma Y, Yanagida T, Yoshio T.    Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric\/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther, <b>16<\/b>:R77, 2014.    doi:10.1186\/ar4518.","DOI":"10.1186\/ar4518"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54.  Yamada Y, Nozawa K, Nakano S, <i>et al.<\/i> Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. Mod Rheumatol, <b>26<\/b>:562-568, 2016. doi: 10.3109\/14397595.2015.1123345.","DOI":"10.3109\/14397595.2015.1123345"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55.  S\u00e1nchez C, D\u00edaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol, <b>61<\/b>:133-168, 2000.","DOI":"10.1016\/S0301-0082(99)00046-5"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56.  Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum, <b>50<\/b>:1239-1247, 2004.","DOI":"10.1002\/art.20156"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57.  Migliorini P, Pratesi F, Tommasi C, Anzilotti C. The immune response to citrullinated antigens in autoimmune diseases. Autoimmun Rev, <b>4<\/b>:561-564, 2005.","DOI":"10.1016\/j.autrev.2005.04.007"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58.  Dema B, Charles N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies (Basel), <b>5<\/b>. pii:E2, 2016.    doi:10.3390\/antib5010002.","DOI":"10.3390\/antib5010002"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59.  Sato T, Fujii T, Yokoyama T, <i>et al.<\/i> Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum, <b>62<\/b>:3730-3740, 2010.    doi:10.1002\/art.27700.","DOI":"10.1002\/art.27700"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60.  Hirohata S, Sakuma Y, Yanagida T, Yoshio T. Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res Ther, <b>16<\/b>:450, 2014.    doi:10.1186\/s13075-014-0450-z.","DOI":"10.1186\/s13075-014-0450-z"},{"key":"60","unstructured":"61.  Perricone C, Pendolino M, Olivieri M, Conti F, Valesini G, Alessandri C. Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. Isr Med Assoc J, <b>17<\/b>:171-178, 2015."},{"key":"61","unstructured":"62.  Conti F, Alessandri C, Bompane D, <i>et al.<\/i> Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations:a role for anti-endothelial-cell antibodies. Arthritis Res Ther, <b>6<\/b>:R366-372, 2004."},{"key":"62","doi-asserted-by":"crossref","unstructured":"63.  Orosz F, W\u00e1gner G, Liliom K, <i>et al.<\/i> Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc Natl Acad Sci U S A, <b>97<\/b>:1026-1031, 2000.","DOI":"10.1073\/pnas.97.3.1026"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64.  Watanabe H, Seino T, Sato Y. Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus. Biochem Biophys Res Commun, <b>321<\/b>:949-953, 2004.","DOI":"10.1016\/j.bbrc.2004.07.051"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65.  Sasajima T, Watanabe H, Sato S, Sato Y, Ohira H. Anti-triosephosphate isomerase antibodies in cerebrospinal fluid are associated with neuropsychiatric lupus. J Neuroimmunol, <b>181<\/b>:150-156, 2006.","DOI":"10.1016\/j.jneuroim.2006.09.003"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66.  Sato S, Watanabe H, Shio K, Kobayashi H, Ohira H. Association of anti-triosephosphate isomerase antibody and MRL\/MpJ-Faslpr mouse. J Neuroimmunol, <b>226<\/b>:110-115, 2010. doi:10.1016\/j.jneuroim.2010.05.041.","DOI":"10.1016\/j.jneuroim.2010.05.041"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67.  Russi AE, Brown MA. The meninges:new therapeutic targets for multiple sclerosis. Transl Res, <b>165<\/b>:255-269, 2015. doi:10.1016\/j.trsl.2014.08.005","DOI":"10.1016\/j.trsl.2014.08.005"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68.  Sirover MA. Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem, <b>66<\/b>:133-140, 1997.","DOI":"10.1002\/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.0.CO;2-R"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69.  Takasaki Y, Kaneda K, Matsushita M, <i>et al.<\/i> Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading autoimmune responses to proliferating cell nuclear antigen multiprotein complexes in lupus patients. Int Immunol, <b>16<\/b>:1295-1304, 2004.","DOI":"10.1093\/intimm\/dxh131"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70.  Delunardo F, Soldati D, Bellisario V, <i>et al.<\/i> Anti-GAPDH Autoantibodies as a Pathogenic Determinant and Potential Biomarker of Neuropsychiatric Diseases. Arthritis Rheumatol, <b>68<\/b>:2708-2716, 2016. doi:10.1002\/art.39750.","DOI":"10.1002\/art.39750"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71.  Sun J, Li X, Zhou H, <i>et al.<\/i> Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus. J Immunol Res, <b>2019<\/b>:7430780, 2019. doi:10.1155\/2019\/7430780. eCollection 2019.","DOI":"10.1155\/2019\/7430780"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/66\/1\/66_2020-02\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T23:41:09Z","timestamp":1587771669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/66\/1\/66_2020-02\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.2020-02","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}